Syngene International Limited (SYNGENE.NS)
INR 681.8
(0.61%)
INR 681.8
(0.61%)
| Year | Long Term Debt | Long Term Debt Growth |
|---|---|---|
| 2023 | 1 Billion INR | -85.78% |
| 2022 | 7.03 Billion INR | -5.19% |
| 2021 | 7.41 Billion INR | 20.09% |
| 2020 | 6.17 Billion INR | 660.59% |
| 2019 | 812 Million INR | -77.55% |
| 2018 | 3.61 Billion INR | -38.22% |
| 2017 | 5.85 Billion INR | -15.12% |
| 2016 | 6.89 Billion INR | -4.88% |
| 2015 | 7.25 Billion INR | 3798.92% |
| 2014 | 186 Million INR | 220.69% |
| 2013 | 58 Million INR | 107.14% |
| 2012 | 28 Million INR | -33.33% |
| 2011 | 42 Million INR | 250.0% |
| 2010 | 12 Million INR | -95.82% |
| 2009 | 287 Million INR | 0.0% |
| Year | Long Term Debt | Long Term Debt Growth |
|---|---|---|
| 2024 Q1 | 1 Billion INR | 0.0% |
| 2024 Q2 | 1 Billion INR | 0.5% |
| 2023 Q4 | 1 Billion INR | -29.28% |
| 2023 Q1 | 4.88 Billion INR | -30.53% |
| 2023 Q2 | 4.16 Billion INR | -14.66% |
| 2023 Q3 | 1.41 Billion INR | -66.08% |
| 2023 FY | 1 Billion INR | -85.78% |
| 2022 Q3 | 5.17 Billion INR | -32.3% |
| 2022 Q4 | 7.03 Billion INR | 35.96% |
| 2022 FY | 7.03 Billion INR | -5.19% |
| 2022 Q1 | 5.43 Billion INR | -26.75% |
| 2022 Q2 | 7.64 Billion INR | 40.62% |
| 2021 FY | 7.41 Billion INR | 20.09% |
| 2021 Q2 | 6.15 Billion INR | 18.32% |
| 2021 Q4 | 7.41 Billion INR | 20.39% |
| 2021 Q3 | 6.16 Billion INR | 0.08% |
| 2021 Q1 | 5.2 Billion INR | -15.75% |
| 2020 Q3 | - INR | -100.0% |
| 2020 FY | 6.17 Billion INR | 660.59% |
| 2020 Q2 | 4.81 Billion INR | 0.0% |
| 2020 Q1 | - INR | -100.0% |
| 2020 Q4 | 6.17 Billion INR | 0.0% |
| 2019 Q4 | 812 Million INR | 0.0% |
| 2019 FY | 812 Million INR | -77.55% |
| 2019 Q1 | - INR | -100.0% |
| 2019 Q3 | - INR | -100.0% |
| 2019 Q2 | 4.36 Billion INR | 0.0% |
| 2018 FY | 3.61 Billion INR | -38.22% |
| 2018 Q2 | 6.5 Billion INR | 0.0% |
| 2018 Q3 | - INR | -100.0% |
| 2018 Q1 | - INR | -100.0% |
| 2018 Q4 | 3.61 Billion INR | 0.0% |
| 2017 Q4 | 5.85 Billion INR | -11.29% |
| 2017 Q2 | 6.98 Billion INR | 0.0% |
| 2017 FY | 5.85 Billion INR | -15.12% |
| 2017 Q3 | 6.6 Billion INR | -5.54% |
| 2017 Q1 | - INR | -100.0% |
| 2016 Q3 | - INR | -100.0% |
| 2016 Q2 | 7.28 Billion INR | 0.0% |
| 2016 FY | 6.89 Billion INR | -4.88% |
| 2016 Q1 | - INR | -100.0% |
| 2016 Q4 | 6.89 Billion INR | 0.0% |
| 2015 FY | 7.25 Billion INR | 3798.92% |
| 2015 Q3 | 370 Million INR | 88.87% |
| 2015 Q2 | 195.9 Million INR | 0.0% |
| 2015 Q1 | - INR | -100.0% |
| 2015 Q4 | 7.25 Billion INR | 1860.0% |
| 2014 Q4 | 186 Million INR | 39.85% |
| 2014 FY | 186 Million INR | 220.69% |
| 2014 Q1 | - INR | 0.0% |
| 2014 Q3 | 133 Million INR | 0.0% |
| 2013 FY | 58 Million INR | 107.14% |
| 2012 FY | 28 Million INR | -33.33% |
| 2011 FY | 42 Million INR | 250.0% |
| 2010 FY | 12 Million INR | -95.82% |
| 2009 FY | 287 Million INR | 0.0% |
| Name | Long Term Debt | Long Term Debt Difference |
|---|---|---|
| Biocon Limited | 129.32 Billion INR | 99.227% |
| Blue Jet Healthcare Limited | 3.79 Million INR | -26285.224% |
| Concord Biotech Limited | 18.87 Million INR | -5199.417% |
| Dishman Carbogen Amcis Limited | 2.45 Billion INR | 59.285% |
| Jubilant Ingrevia Limited | 4.25 Billion INR | 76.502% |
| Lyka Labs Limited | 429.06 Million INR | -133.064% |
| Panacea Biotec Limited | 209.9 Million INR | -376.417% |
| Piramal Pharma Limited | 24.83 Billion INR | 95.974% |
| SMS Lifesciences India Limited | 331.45 Million INR | -201.705% |
| Supriya Lifescience Limited | 50.2 Million INR | -1892.032% |
| TAKE Solutions Limited | 7.5 Million INR | -13233.333% |
| Zota Health Care Limited | 631.64 Million INR | -58.318% |